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Introduction
Since the discovery of small interfering RNAs (siRNA) byMello and
Fire in 1998, the biological importance and potential therapeutic
target of various forms of small RNAs have rapidly emerged.
MicroRNAs (miRs) are small (20–22 nucleotide), non-coding RNA
molecules that are encoded by genomic DNA and were discovered
in 1993 byAmbros and colleagues [1].miRNAs affect a broad range
of biological functions including cell proliferation, differentiation,
immunity, tissue remodeling, and cancer development [2,3].
The biogenesis ofmiRNAs ismore complex than earlier thought
andhas been reviewed extensively. Brieﬂy,miRNAs are transcribed
in the nucleus asmono or polycistronicmRNAs, known as pri-miR-
NAs (Fig. 1). Thepri-MiRs are cleavedby the ribonucleaseDrosha to
yield pre-miRNAs (60–90 bp). The pre-Mirs are then exported from
the nucleus to the cytoplasm via the exportin 5 complex (reviewed
in [4]), where they are further processed by ribonuclease Dicer to
yieldmiRNA duplexes (20–22 bp).miRNA duplexes are then trans-
ferred to the RNA-induced silencing complex (RISC) where the
mature guide strand becomes associated with Argonaute proteins
and the passenger strand gets expelled from RISC and degraded
(Fig. 1). It is known that a singlemiRNA canhave hundreds of target
mRNAs and that a given mRNA can be targeted by numerous miR-Journal of Hepatology 20
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the degree of complementarity between the miRNA and mRNAs
[5]. Imperfect base pairing ofmiRNAwith targetmRNAUTR results
in the inhibition of mRNA translation or mRNA degradation, and
perfect base complementarity almost always results in mRNA
cleavage by Argonaute 2 [5]. Recent studies suggest that miRNAs
can also interact with the DNAmethylation machinery andmodu-
late the chromatin state [6]. Curiously, even slight changes in abun-
dances of even a few miRNAs can substantially alter cellular
physiology and contribute to the development of a disease. Consis-
tent with this notion, alterations in miRNAs proﬁles have recently
been described in various types of acute and chronic liver diseases
including alcoholic andnon-alcoholic fatty liver diseases, viral hep-
atitis, primary biliary cirrhosis, liver ﬁbrosis, and hepatocellular
carcinoma (Table 1).
In this review, we will discuss the current knowledge of the
roles for miRNAs in liver disease and novel tools to change the
abundance of miRNAs in the liver in animals.
MicroRNAs as disease-speciﬁc targets for modulating liver
diseases
The importance of miRNAs in liver diseases has been the focus of
many recent investigations. The physiological importance of
miRNA in the liver has been recognized in regulation of metabolic
pathways, immunity, viral hepatitis, cancer, and liver ﬁbrosis
[2,3,7]. Among ‘‘organ-speciﬁc’’ miRNAs, miR-122 uniquely
represents 70% of the total miRNAs in hepatocytes. Curiously,
the pri- and pre-miRs of miR-122 are regulated in a circadian
manner [8]. This is a very surprising observation given the ﬁnding
that the turnover of mature miR-122 is several weeks in the liver,
pointing to possible functional roles for the precursor molecules
of miR-122. The targets of miR-122 include genes of cholesterol
and lipid metabolism, and it also plays an important host factor
in HCV infection [8,9]. Other miRNAs were found abnormally
expressed in various forms of liver diseases in the liver or in
the circulation [2,3,7]. Indeed, the concept that miRNAs could
serve as potential serum/plasma biomarkers of disease is gaining
attention in liver disease.
MicroRNA silencing in viral hepatitis
Perhaps the most compelling evidence for the therapeutic feasi-
bility of miRNA inhibition comes from studies in hepatitis C virus12 vol. 57 j 462–466
CytoplasmNucleus
RISC/miRNA
miRNA gene
pri-miRNA
miRNA-miRNA*
duplex
pre-miRNA
Antisense
strand
Degrade?
Sequester/degrade
Sense
strand
Nanoparticles 
mediated 
miRNA delivery
Perfect
complementarity
Partial
complementarity
mRNA degrade Inhibition at
translation
Ago
3’ or 5’ UTR
of target mRNA
Ago
miRNA mimics
ASO:
- LNA
- Antagomirs
- 2'-O-methyl 
- miR Zip
AAV
Fig. 1. miRNA biogenesis and therapeutic delivery. miRNA are transcribed as
pri-miRNA in the nucleus and exported to the cytoplasm as pre-miRNA and later
processed as mature miRNAs. Sense or guide strand is loaded into the Ago
complex, which is named RNA inducing silencing complex (RISC). Depending on
complementary of sense strand to target gene, either the target mRNA is
degraded (100% complementary) or translation is inhibited (partial complemen-
tary). miRNA function can be inhibited by using antisense oligonucleotides (ASO)
such as lock nucleic acid (LNA), antagomirs, miR ZIp, 20-O-methyl, etc. Nanopar-
ticles or adeno-associated vectors (AVV) can be used for tissue-speciﬁc anti-
miRNA delivery particularly in in vivo systems. For overexpression of a particular
miR, miRNA mimics can be used directly or delivery can be mediated by AAV or
nanoparticles.
JOURNAL OF HEPATOLOGYinfection. The role of miR-122 has received attention in HCV
infection as miR-122 has been shown to enhance the RNA abun-
dance of HCV by targeting the viral 50 non-coding region [10].
While the exact role of miR-122 in HCV replication is still not
fully understood, in vivo studies in chronic HCV infected
chimpanzees showed a potent inhibition of circulating HCV virus
levels after administration of modiﬁed, anti-sense miR-122 mol-
ecules, so-called antagomirs [11]. HCV RNA levels were decreased
in the animal receiving the highest dose of the miR-122 antago-
mir and this was associated with improvements in liver histol-
ogy. Importantly, there was no evidence of viral breakthrough
based on deep sequencing analysis of the viral 50 non-coding
region (NCR) [11]. These observations support the feasibility of
disease manipulation in HCV infection with a miRNA-silencingJournal of Hepatology 201approach. miR-122 has numerous target genes of which hemox-
ygenase-1 (HO-1), an inducible enzyme involved in oxidative
stress and bilirubin metabolism, has been shown to affect both
HCV and HBV virus levels [12]. It was shown that miR-122 inhi-
bition with a miR-122 antagomir signiﬁcantly increased HBsAg
and HBeAg secretion in HuH7 cells [12]. Interestingly, miR-122
overexpression in HepG2 cells resulted in a marked reduction
of HBsAg and HBeAg expression. This was associated with
suppression of HO-1 and decreased HBV replication suggesting
that miR-122 is antiviral for HBV, but proviral for HCV [12].
Further understanding of the role of miR-122 in hepatocytes
and its role in the host–virus interactions will help reconcile
these observations.
MicroRNA targets in fatty liver disease
Both alcoholic and non-alcoholic fatty livers (NAFLD) show dys-
regulation of miRNAs in animal models and in human samples
[3,13]. In human NAFLD, 23 miRNAs regulating cell proliferation,
apoptosis, inﬂammation, oxidative stress and metabolism were
either overexpressed or underexpressed [14]. Changes in miRNAs
in the metabolic syndrome that underpin NAFLD and non-alco-
holic steatohepatitis (NASH) have recently been reviewed in rel-
evance to potential therapeutic strategies [15].
In alcoholic liver disease, the role of inﬂammation and Kupffer
cells (KCs) activation resulting in increased TNFa production has
been long established. The Szabo laboratory has recently shown
that upregulation of miR-155 in KCs after chronic alcohol feeding
contributes to sensitization of KCs to gut-derived LPS [16]. Specif-
ically, alcohol upregulated miR-155 via NF-jB activation, leading
to stabilization of TNFa mRNA. Further studies are needed to
evaluate the in vivo relevance of these ﬁndings by targeting
miR-155 in KCs.
Liver ﬁbrosis
Liver ﬁbrosis is a complex process where activation of stellate
cells and expression of matrix metalloproteinases and tissue
inhibitors of metalloproteinase play important roles. A differen-
tial expression of miRNA proﬁles was reported in stellate cells
from ﬁbrotic rat livers [17]. In depth investigation of miR-150
and miR-194 revealed signiﬁcantly reduced levels in ﬁbrosis
and found that both of these miRNAs inhibit stellate cell activa-
tion via inhibition of c-myb and rac1 expression. They also dem-
onstrated that overexpression of miR-150 or miR-194 could
reverse the activated phenotype of stellate cells in a human stel-
late cell line thereby identifying miR-150 and miR-194 as the
potential therapeutic targets in ﬁbrosis [17]. The family of miR-
NA-29 (miR-29a, 29b1, 29b2, and 29c) also plays a role in mouse
models of ﬁbrosis (carbon tetrachloride or bile duct ligation mod-
els) and as well in human [18]. Mechanistically, it was shown
that treatment of hepatic stellate cells with TGFb suppressed
miR-29 expression suggesting that part of the ﬁbrogenic effects
of TGFb is mediated via miR-29 downregulation [18]. TGFb is also
a direct target of miR-29 and thus, miR-29 may act as an ampli-
ﬁer for liver ﬁbrosis. In another study, expression of miR-199a,
199a⁄, 200a, and 200b was found to be correlated with the degree
of progression of liver ﬁbrosis in chronic hepatitis C patients [19].
Overexpression of these miRNAs in LX-2 cells (hepatic stellate
cell line) resulted in the induction of ﬁbrotic genes such as TIMP1,
MMP13, and alpha1 procollagen, indicating a role of these miRs in2 vol. 57 j 462–466 463
Table 1. Aberrant microRNAs expression in liver disease and reported therapeutic approaches.
Disease miRNAs Expression Delivery approach
Hepatitis C miR-296, miR-351, miR-155, miR-146
miR-29, miR-221, mir-222, miR-181a
Up
Down
LNA, AAV, antagomirs, 2’-O-Me, anti-
sense oligonucleotides*
miRNA mimics*
Hepatitis B miR-373, miR-370, miR-523
miR-122, miR-223, miR-29c, mir-199b, miR-198
Up
Down
Antisense oligonucleotides*, LNA*
miRNA mimics*
NASH miR-155, miR-34a, miR-146b, miR-200b,
miR-122, miR-617, miR-451
Up
Down
2′-O-Me (antagomirs), antisense oligo-
nucleotides*
miRNA mimics*
ALD miR-155, miR-705, miR-1224, miR-212
miR-182, miR-183, miR-199
Up
Down
Antisense oligonucleotides*
miRNA mimics*
Drug-
induced 
liver injury
miR-466 family, miR-710,
miR-328, miR-721, miR-1224
miR-122, miR-101a, miR-29 family, miR-101b, miR-21, miR-19b
Up
Down
LNA, AAV, antagomirs, nanoparticles
(potential approaches)
miRNA mimics, AAV 
(potential approaches)
HCC miR-21, miR-221, miR-22, miR-15, miR-517a 
miR-122, miR-29 family, miR-26a, miR-124, let-7 family members, 
miR-199a/b-3p
Up
Down
AAV, LNA, antisense oligonucleotides*
miRNA mimics*, AAV
miR-199a, miR-200, miR-21, let-7 family members, mir-223, miR-34c
miR-29 family, miR-122, miR-146a, miR-15b, miR-150, miR-194
Up
Down
Antisense oligonucleotides*
miRNA mimics*
Liver fibrosis
⁄ In vitro studies.
LNA, lock nucleic acid; AAV, adeno-associated vector.
Clinical Application of Basic Sciencethe initiation of liver ﬁbrosis [19]. The role of miRNAs in hepatic
stellate cell differentiation has been reviewed elsewhere [7].
From the potential therapeutic point of view, it is tempting to
speculate that overexpression or inhibition of miRNAs could
attenuate liver ﬁbrosis. However, tissue and cell-speciﬁc delivery
of miRNA duplexes remains to be a technical challenge and has
been elegantly reviewed [20].
HCC and other cancers in the liver
Numerous studies indicate that loss of miRNAs can contribute to
liver tumorigenesis. It was shown that ectopic expression of a
single miRNA, miR-26a, could reverse HCC progression in a
mouse model of liver cancer [21]. In another study, myc-induced
liver tumors in mice resulted in concomitant downregulation of
selective miRNAs, including miR-15a/16, miR-26a, miR-24a,
miR-150, and miR-195 [22]. MiR-26a regulates the expression
of cyclin D2 and E2 and induces G1 arrest of human liver cancer
cells; thus, disturbed expression of miR-26a dysregulates cell
cycle and proliferation as seen in liver cancer cells but inhibition
of miR-26a through therapeutic modulation could prevent these
devastating effects. Indeed, overexpression of miR-26a in human
liver tumor cells resulted in an increased number of cells in G1
stage and fewer cells in the proliferative S cycle [21]. In vivo data
was consistent with this result, as forced expression of miR-26a
with an AAV2 vector prevented development of liver tumors [21].
Experimental data suggest that, in addition to HCC, efﬁcient
in vivo targeting can also attenuate metastatic tumors in the liver.
The pro-metastatic miRNA-182 was the target of therapeutic
intervention. In vitro inhibition of miR-182 results in apoptosis
and represses invasion in melanoma metastasis. Anti-miR-182464 Journal of Hepatology 201oligonucleotide, synthesized with 20 sugar modiﬁcations and a
phosphothioate backbone, was used in a mouse model of mela-
noma and it was found that anti-miR-182 treatment resulted in
a lower burden of liver metastasis [23].Methods to modulate the abundance of miRNAs in the liver
The above examples reveal that modulation of microRNA expres-
sion in the liver can have dramatic consequences on liver pathol-
ogy and disease. Thus, it is very desirable to be able to express
miRNAs and to sequester miRNAs in the liver.
Adeno-associated virus (AAV)-mediated gene delivery
It is known that adeno-associated virus (AAV) vectors can be used
to express genes or small non-coding RNAs in the liver. AAV vec-
tors can be designed to express precursors or small interfering
inhibitors of miRNAs with relatively good speciﬁcity in hepato-
cyte delivery. Among AAV serotypes, the use of AAV8 was found
to be advantageous since this envelope does not seem to be asso-
ciated with human AAV infections and thus immunological mem-
ory should not be a concern when using it clinically [24]. In
contrast, the use of AAV2 for in vivo therapy was limited because
of early immunologic memory of AAV infections [25]. More
recently, AAV9 vector was shown to have liver speciﬁcity. Expres-
sion of miR-122 target sequences into the 30-UTR of AAV vectors
revealed liver-speciﬁc delivery without affecting other organs,
including the heart [24]. Yet, AAV-expressed genes are presum-
ably unmodiﬁed and, thus, their afﬁnity to target RNAs and their
turnover cannot easily be manipulated.2 vol. 57 j 462–466
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For decades, researchers in both academia and industry have
studied methods to deliver small, efﬁcacious oligonucleotides to
speciﬁc target organs in animals. While it has been difﬁcult to
target oligonucleotides to any organ, recent advantages have
shown that the liver can take up, especially single-stranded oligo-
nucleotides either unformulated or in particle-associated
complexes.
Delivery of antisense oligonucleotides (antagomirs) to the liver
Antagomirs are nucleic acid sequences with antisense polarity to
miRNAs. They sequester miRNAs in small duplexes that do not
induce innate immune responses. To enhance stability in serum
and in cells, antagomirs can be further chemically modiﬁed by
introducing different moieties such as ‘‘20-O-methoxyethyl
groups’’ and phosphothioate linkages. Their uptake by the liver
can also be enhanced by adding cholesterol moieties [26].
One of the champion antagomirs are locked nucleic acids
(LNA) that consist of a class of bicyclic conformational analogues
of RNA. LNA modiﬁcations comprise one or more nucleotide
building blocks in which a methylene bridge connects the ribose
moiety either in the C30-endo or C20-endo conformation [27].
Addition of LNA to DNA or RNA not only enhances the afﬁnity
for complementary sequences but also increases the stability
in vivo [27]. LNAs directed against miR-122, which are applied
to non-human primates [11] and humans by either intravenous
or subcutaneous injection, locate quickly to the liver where they
sequester miR-122 for as long as seven weeks, after which the
LNAs get secreted from the organism. Importantly, cholesterol
abundance dropped in treated animals without any adverse
effects on liver function [11]. This ﬁnding suggests that LNAs
can be used to functionally sequester the highly abundant, low-
turnover guide strand of miR-122, without any off-targets effects
from the passenger miR-122 strand. In general, the off-target
effects can be speciﬁc (non-targeted mRNA) and non-speciﬁc
(immune activation) and are reviewed in detail in [20].
Delivery of small duplex RNAs using cationic lipid-based and
nanoparticle-based delivery systems
While delivery of small, single-stranded RNA to the liver is now
possible, the delivery of small interfering RNAs or duplex miRNA
mimetics to the liver is very cumbersome. In contrast to LNAs,
duplex RNAs need to be delivered by cationic lipids or nanopar-
ticles. However, exit from the delivery vehicles or the cellular
endosomes is very inefﬁcient. While off-target effects of the pas-
senger strand can be minimized by chemical modiﬁcation of the
RNA duplex, activation of toll-like receptors and other innate
immune responses needs to be carefully monitored.
A recent report described a method to deliver miR-133b mim-
ics into lung tissue. To increase the effectiveness of cellular
uptake, cationic lipids were used to condense miRNAs to form
lipoplexes [28]. Pre-miR-133b containing lipoplexes were deliv-
ered into mice via tail vein to enhance miR-133b levels in lung
and around 30% pre-miR-133b lipoplexes were found in lung tis-
sue. Yet, despite increased accumulation of pre-miR-133b lipo-
plexes in the lung, the complexes were also found in other
organs such as kidney, liver, and spleen.
Nanoparticle-mediated miRNA delivery is gaining attention in
the ﬁeld. In the past, lipid nanoparticles (LNPs) have beenJournal of Hepatology 201successfully used to deliver RNA duplexes in the liver, including
stellate cells [29]. Later on, anti-miR-132-containing nanoparti-
cles speciﬁcally targeted to integrin aVb3 receptor were delivered
into mice to restore p120RasGAP expression in the tumor endo-
thelium [30]. The advantage of this formulation is that it speciﬁ-
cally targets the avb3 integrin-positive endothelial cells. In vivo
silencing of miR-122 by interfering nanoparticles was recently
reported in mice [31]. Recently PEGylated LPH (liposome-polyca-
tion-hyaluronic acid) nanoparticles along with modiﬁed cyclic
RGD peptide (cRGD) were used for speciﬁc and efﬁcient delivery
of anti-mir-296 AMO in mice [32]. These examples show that
miRNA duplexes can be delivered to speciﬁc tissues, yet off-target
effects and effects on innate immune responses need to be
examined as discussed above.Remaining challenges
Despite the growing literature in miRNA ﬁeld, miRNA-based ther-
apies are still in infancy. There are several challenges in the ﬁeld
because of lack of tissue/cell speciﬁcity, suboptimal delivery sys-
tems, insufﬁcient cellular uptake, off-target effects and cellular
toxicity. While the development of novel therapeutic strategies
mostly concentrates on silencing of miRNAs using various RNA
interference approaches, restoration of insufﬁciently expressed
miRNAs needs to be considered in the potential therapeutic
armamentaria. In conclusion, while improvements in miRNA
delivery systems are encouraging, more work is needed to
evaluate their long-term in vivo efﬁcacy, speciﬁcity, and systemic
toxicity prior to future translation of these emerging technologies
and strategies to direct patient care.Financial support
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